Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Decision Making and Interventions During Interfacility Transport of High-Acuity Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection

Ruben D. Troncoso Jr, MD, MPH1,2,*, Eric M. Garfinkel, DO1, David Leon, MD1, Sandra M. Lopez, MD1, Andrew Lin, MD1, Dennis Jones, DNP, RN, NRP2, Shawn Trautman, BSN, RN2, Matthew J. Levy, DO, MSc1,2, Asa M. Margolis, DO, MPH, MS1,2

1 Department of Emergency Medicine, Johns Hopkins University School of Medicine, Baltimore, MD
2 Johns Hopkins Lifeline Critical Care Transportation Program, Johns Hopkins University School of Medicine, Baltimore, MD

ABSTRACT

Objective: There are limited data regarding the typical characteristics of coronavirus disease 2019 (COVID-19) patients requiring interfacility transport or the clinical capabilities of the out-of-hospital transport clinicians required to provide safe transport. The objective of this study is to provide epidemiologic data and highlight the clinical skill set and decision making needed to transport critically ill COVID-19 patients.

Methods: A retrospective chart review of persons under investigation for COVID-19 transported during the first 6 months of the pandemic by Johns Hopkins Lifeline was performed. Patients who required interfacility transport and tested positive for severe acute respiratory syndrome coronavirus 2 by polymerase chain reaction assay were included in the analysis.

Results: Sixty-eight patients (25.4%) required vasopressor support, 35 patients (13.1%) were pharmacologically paralyzed, 15 (5.60%) were prone, and 1 (0.75%) received an inhaled pulmonary vasodilator. At least 1 ventilator setting change occurred for 59 patients (22.0%), and ventilation mode was changed for 11 patients (4.10%) during transport.

Conclusion: The safe transport of critically ill patients with COVID-19 requires experience with vasopressors, paralytic medications, inhaled vasodilators, prone positioning, and ventilator management. The frequency of initiated critical interventions and ventilator adjustments underscores the tenuous nature of these patients and highlights the importance of transport clinician reassessment, critical thinking, and decision making.

© 2021 Air Medical Journal Associates. Published by Elsevier Inc. All rights reserved.

The coronavirus disease 2019 (COVID-19) pandemic has threatened to overwhelm hospitals and health care systems across the globe.1 Interfacility transport programs have been tasked with the movement of these critically ill patients to tertiary and quaternary care centers to receive additional clinical expertise and resources. These transport programs also help facilitate the regionalization of care to mitigate hospitals becoming disproportionately overwhelmed by the number and/or acuity of patients. Although data are emerging regarding the characteristics of COVID-19 patients transported by emergency medical services systems,2 there is only limited information describing the typical illness severity of patients cared for during critical care transport.3-5 Furthermore, there is a paucity of literature describing the interventions and decision making by critical care transport clinicians during ground and air transport.

Johns Hopkins Lifeline (Lifeline) is a high-volume, high-acuity critical care transport program responsible for the movement and care of approximately 16,000 intrafacility transports, 5,500 interfacility ground transports, and 800 air transports per year predominantly throughout Maryland and Washington DC with occasional transports between Delaware, Pennsylvania, and Virginia. Created in response to the Ebola pandemic of 2014 to 2015, the Lifeline Special Operations Response Team (SORT) is a subset of Lifeline team members specially trained in the movement of patients with severe illness and high risk of transmission.
high-consequence infectious diseases. Given the specific training and knowledge of the SORT members, this team was dedicated to the movement of patients under investigation (PUI) for COVID-19 and patients with confirmed COVID-19 infections into and throughout the Johns Hopkins Health System. A SORT mission included the addition of a safety officer along with the patient care team. Lifeline performed its first COVID-19 interfacility transport on February 29, 2020, approximately 11 days before the disease was declared a pandemic by the World Health Organization. This article is a novel observational study that describes the characteristics of COVID-19 patients and the clinical management by the Lifeline transport nurses and paramedics during the first 6 months of the pandemic.

**Methods**

This study was a retrospective chart review of patients with confirmed COVID-19 and PUIs for COVID-19 transported by Lifeline from February 29, 2020, to August 31, 2020. Patients who required interfacility transport and tested positive for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RNA by polymerase chain reaction (PCR) assay were included in the analysis. Patients were excluded if they required intrafacility transport or if they did not have a positive PCR assay for SARS-CoV-2 RNA. Patient characteristics before transport and clinical management during transport were captured via chart review (Zoll Data Systems, Broomfield, CO). All patients with confirmed COVID-19 and PUIs were transported by Lifeline SORT.

The pretransport data included patient demographics, vital signs, end-tidal carbon dioxide levels, and supplemental oxygen requirements. Patient temperature was inconsistently reported and was excluded. In addition, critical care interventions implemented before transport were recorded and included vasopressor administration, pharmacologic paralysis, prone position, and inhaled pulmonary vasodilator administration.

Clinical management decisions during transport were recorded. Variables of interest included ventilator changes, vasopressor initiation, pharmacologic paralysis initiation, initiation of prone position, administration of inhaled pulmonary vasodilators, and endotracheal intubation.

Descriptive statistics were used to report the findings of the study. Means were reported for continuous variables, and proportions were reported for dichotomous variables. Ninety-five percent confidence intervals (CIs) were reported for the calculated means and proportions. STATA 15.1 software (StataCorp LLC, College Station, TX) was used for data analysis.

The study was approved by the Johns Hopkins Institutional Review Board and conducted according to the Strengthening the Reporting of Observational Studies in Epidemiology reporting guidelines.

| Clinical Characteristics | Mean (95% CI) | Number of Patients (% 95% CI) |
|--------------------------|--------------|--------------------------------|
| Age, y                   | 57.8 (54.9-60.7) | 149 (55.6, 49.6-61.5) |
| Sex                      |               |                                |
| Male                     | 119 (44.4, 38.5-50.4) |
| Female                   |               |                                |
| Vital signs before transport |                     |                                |
| Blood pressure, mm Hg    |               |                                |
| Systolic                 | 124 (121-127) |
| Diastolic                | 76.7 (69.1-72.3) |
| Heart rate, beats/min    | 89.5 (87.3-91.7) |
| Respiratory rate, breaths/min | 23.2 (22.3-24.1) |
| Oxygen saturation by pulse oximetry, % | 95.7 (95.2-96.1) |
| End-tidal carbon dioxide before transport | 39.6 (37.4-41.9) |
| Mode of oxygenation      |               |                                |
| Room air                 | 58 (21.6, 17.1-27.0) |
| Nasal cannula            | 77 (28.7, 23.6-34.5) |
| Air entrainment mask     | 1 (0.37, 0.05-2.62) |
| Tracheostomy mask        | 1 (0.37, 0.05-2.62) |
| Nonebreather mask        | 7 (2.61, 1.25-5.39) |
| High flow nasal cannula  | 14 (5.22, 3.11-8.605) |
| Noninvasive positive-pressure ventilation | 2 (0.75, 0.19-2.95) |
| Invasive positive-pressure ventilation | 108 (40.3, 34.6-46.3) |
| Interventions before transport |                     |                                |
| Vasopressor support      | 68 (25.4, 20.5-30.9) |
| Neuromuscular paralysis  | 35 (13.1, 9.51-17.7) |
| Prone positioning        | 15 (5.60, 3.39-9.09) |
| Inhaled nitric oxide     | 2 (0.75, 0.19-2.95) |

* End-tidal carbon dioxide levels were available for 116 patients.

Figure 1. A flowchart of the patient selection for inclusion in the analysis.
Results

Between February 29, 2020, and August 31, 2020, Lifeline completed 1,089 PUI transports. There were 381 (35.0%) interfacility transports and 708 (65.0%) intrahospital transports. Two hundred eighty-two (74.0%) interfacility transport patients were COVID-19 positive, and 11 (3.9%) were transported by air. There were 14 (5.0%) incomplete charts that were excluded from analysis. A total of 268 patients were included in the final analysis (Fig. 1).

Table 1 describes patient demographics and pretransport clinical data for COVID-19 patients requiring interfacility transport. The mean age of patients and the number of comorbidities were 57.8 years (95% CI, 54.9-60.7) and 1.53 (95% CI, 1.37-1.70), respectively. Before transport, 210 patients (78.4%; 95% CI, 73.0%-82.9%) required supplemental oxygen, and 108 (40.3%; 95% CI, 34.6%-46.3%) were intubated for mechanical ventilatory support (Fig. 2). Sixty-eight patients (25.4%; 95% CI, 20.5%-31.0%) received vasopressor support, 35 (13.1%; 95% CI, 9.51%-17.7%) were pharmacologically paralyzed, 15 (5.60%; 95% CI, 3.39%-9.09%) were in the prone position, and 1 (0.75%; 95% CI, 0.19%-2.95%) received an inhaled pulmonary vasodilator. No patients received extracorporeal membrane oxygenation (ECMO) support.

Clinical decisions and interventions initiated by the Lifeline transport team are described in Table 2. Lifeline clinicians initiated vasopressor support for 18 patients (6.71%; 95% CI, 4.26%-10.4%), pharmacologic paralysis on 12 patients (4.48%; 95% CI, 2.55%-7.73%), and prone positioning for 1 patient (0.37%; 95% CI, 0.05%-2.62%). Among the 108 patients who were intubated, Lifeline made at least 1 ventilator setting change for 59 patients (22.0%; 95% CI, 17.4%-27.3%) and changed the mode of ventilation for 11 patients (4.10%; 95% CI, 2.28%-7.27%). No patients required intubation during transport. Figure 3 shows the cumulative percentage of patients requiring the studied clinical interventions.

Discussion

The COVID-19 pandemic has resulted in the frequent transfer of patients due to capacity limitations and illness severity. This retrospective analysis is the largest study to date describing the acuity and management required for COVID-19 patients undergoing interfacility transport. We have found these patients were frequently high acuity and required changes in management during transport to optimize care. Nearly 80% of patients received supplemental oxygen meeting the criteria for severe COVID-19 infection. Over half of these patients required invasive mechanical ventilation for respiratory failure meeting the definition for critical COVID-19 infection.9

Invasive mechanical ventilation was the most common intervention that a Lifeline clinician was required to manage. Greater than 11% of the intubated patients were paralyzed to optimize respiratory support, which emphasizes the critical illness of the study population. This is also reflected by the ventilator changes required during transport.

Table 2

Clinical Interventions for Patients Requiring Interfacility Transport by Lifeline Special Operations Response Team Who Were Positive for Severe Acute Respiratory Syndrome Coronavirus 2 RNA by Polymerase Chain Reaction (N = 268)

| Transport Characteristics                  | Number of Patients (%, 95% CI) |
|-------------------------------------------|---------------------------------|
| Interventions by transport team           |                                 |
| Vasopressor initiation                     | 18 (6.7, 4.26-10.4)             |
| Chemical paralysis initiation              | 12 (4.48, 2.56-7.73)            |
| Pronation of patient                       | 1 (0.37, 0.05-2.62)             |
| At least 1 ventilator setting change       | 59 (22.0, 17.4-27.3)            |
| Ventilation mode change                    | 11 (4.10, 2.28-7.28)            |

CI = confidence interval.
The COVID-19 pandemic has resulted in the need for hospitals and health care systems to continuously evaluate their capacity and ability to provide optimal care for COVID-19 patients. The ability to regionalize care requires the use of highly trained critical care transport teams. Given the current and anticipated surge of COVID-19, there will likely be a high demand for critical care transport services.

Conclusions

The safe transport of these patients is paramount and requires competency and comfort with the titration and initiation of vasopressors, paralytic medications, and ventilator management. Although less common in the first 6 months, knowledge about how to transport patients requiring inhaled nitric oxide is also necessary. The frequency of Lifeline initiated vasopressors, pharmacologic paralysis, and ventilator adjustments underscores the tenuous nature of these patients and highlights the importance of transport clinician reassessment and critical thinking.

This report provides valuable insight to the skills needed by these out-of-hospital clinicians as well as the complexity of patients who require transport. Notable limitations include the use of data from a single system, absence of scene transports, and the use of paramedic/nurse crew configuration.

Acknowledgments

Chad Bowman, Heidi Hubble, Ben Quintanilla, and all of the Lifeline Special Operations Response Team members were vital in developing and implementing the training, education, management protocols, and transport systems used by Lifeline Special Operations Response Team SORT during the coronavirus disease 2019 pandemic and provided invaluable insight toward the completion of this study. We would also like to acknowledge STAT MedEvac for their fantastic support and offered invaluable insight toward the completion of this study.

References

1. Mareiniss DP. The impending storm: COVID-19, pandemics and our overwhelmed emergency departments. Am J Emerg Med. 2020;38:1293–1294.
2. Yang BY, Barnard LM, Emert JM, et al. Clinical characteristics of patients with coronavirus disease 2019 (COVID-19) receiving emergency medical services in King County, Washington. Jama Netw Open. 2020;3:e2014549.
3. Allen R, Wanersdorfer K, Zebley J, Shapiro G, Coullahan T, Sarani B. Interhospital transfer of critically ill patients because of coronavirus disease 19–related respiratory failure. Am J Med. 2020;39:408–501.
4. Hilbert-Carius P, Braun J, Abu-Zidan F, et al. Pre-hospital care & interfacility transport of 385 COVID-19 emergency patients: an air ambulance perspective. Scand J Trauma Resusc Emerg Med. 2020;28:94.
5. Tien H, Sawadsky B, Lewell M, Peddle M, Durham W. Critical care transport in the time of COVID-19. CJEM. 2020;22:S84–S88.
6. Garibaldi BT, Kelen GD, Brower KG, et al. The creation of a biocontainment unit at a tertiary care hospital. The Johns Hopkins Medicine experience. Ann Am Thorac Soc. 2016;13:600–608.
7. Garfinkel E, Lopez S, Troncoso Jr R, et al. A critical care transport program’s innovative approach to safety during the coronavirus disease 2019 pandemic. Air Med J. 2021;40:112–114.
8. Ghebreyesus TA. WHO Director-General’s opening remarks at the media briefing on COVID-19. World Health Organization; 2020. Available at: https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19–11-march-2020 Accessed December 20, 2020.
9. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China. JAMA. 2020;323:1239–1242.
10. DellaVolpe JD, Lovett J, Martin-Gill C, Guyette FX. Transport of mechanically ventilated patients in the prone position. Prehosp Emerg Care. 2016;20:643–647.
11. Flabouris A, Schuetzke P, Garner A. ARDS with severe hypoxia - aeroomedical transportation during prone ventilation. Anaesth Intensive Care. 2003;31:675–678.
12. Hersey D, Witter T, Kovacs G. Transport of a prone position acute respiratory distress syndrome patient. Air Med J. 2018;37:206–210.
13. Sartini C, Tresoldi M, Scarpellini P, et al. Respiratory parameters in patients with COVID-19 after using noninvasive ventilation in the prone position outside the intensive care unit. JAMA. 2020;323:2338–2340.
14. Caputo ND, Strayer RJ, Levitan R. Early self-proning in awake, non-intubated patients in the emergency department: a single ED’s experience during the COVID-19 pandemic. Acad Emerg Med. 2020;27:375–378.
15. Elharrar X, Trigui Y, Dols A-M, et al. Use of prone positioning in nonintubated patients with COVID-19 and hypoxemic acute respiratory failure. JAMA. 2020;323:2336–2338.
16. Solorson K, Weatherald J, Parhar KKS. Tolerability and safety of awake prone positioning COVID-19 patients with severe hypoxemic respiratory failure. Can J Anaesth. 2021;68:64–70.
17. Zang X, Wang Q, Zhou H, Liu S, Xue X. Efficacy of early prone position for COVID-19 patients with severe hypoxia: a single-center prospective cohort study. Intensive Care Med. 2020;46:1927–1929.
18. Seethala RR, Frakes MA, Cocchi MN, et al. Feasibility and safety of prone position transport for severe hypoxemic respiratory failure due to coronavirus disease 2019. Crit Care Explor. 2020;2:e0293.
19. Alvarez RA, Berra L, Gladwin MT. Home nitric oxide therapy for COVID-19. Am J Respir Crit Care Med. 2020;202:16–20.
20. Ferrer M, Santini A, Protti A, et al. Inhaled nitric oxide in mechanically ventilated patients with COVID-19. J Crit Care. 2020;60:159–160.
21. Longobardo A, Montanari C, Shulman R, Benhalim S, Singer M, Arulkumaran N. Inhaled nitric oxide minimally improves oxygenation in COVID-19 related acute respiratory distress syndrome. Br J Anaesth. 2020;126:e44–e46.